The Experts below are selected from a list of 186 Experts worldwide ranked by ideXlab platform

Mitchell P Rosen - One of the best experts on this subject based on the ideXlab platform.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation in split semen samples
    Reproductive Biomedicine Online, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    Capsule Microfluidic sorting of unprocessed semen allows for the selection of clinically usable sperm with lower DNA fragmentation than standard processing. Objective To determine if microfluidic sorting improves the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation. Design Blinded, controlled laboratory study. Setting Academic medical center. Specimens Consecutively collected routine semen analysis samples (n=70). Intervention(s) For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation and sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by Sperm Chromatin Dispersion (SCD) test. Outcome Measure DNA Fragmentation Index (DFI) was calculated as number of cells with fragmented DNA divided by the number of cells counted per slide. Results The median DFI in unprocessed samples was 21% (IQR 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation and unprocessed samples. The median DFI for chip specimens was 0% (IQR 0–2.4) while those processed by Density Gradient Centrifugation had a median DFI of 6% (IQR 2-11). Unprocessed samples in the highest DFI quartile (DFI range 31–40%) had median DFI of 15% (IQR 11–19%) after Density-Gradient Centrifugation and DFI 0% (IQR 0–1.9%) after processing with the microfluidic chip (p = 0.02). Conclusion Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. Future studies will be expending the sample size, and validate if the use of chip can be translated into difference in pregnancy rates. Conflict of Interest Disclosures Utkan Demirci, Ph.D. is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc., and Koek Biotech. Mitchell Rosen, M.D. is a member of the Clinical Advisory Board for DxNow Inc. Funding None.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation with swim up in split semen samples
    Human Reproduction, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    STUDY QUESTION: Does microfluidic sorting improve the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation? SUMMARY ANSWER: Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. WHAT IS KNOWN ALREADY: Microfluidic devices have been explored to sort motile and morphologically normal sperm from a raw sample without Centrifugation; however, it is uncertain whether DNA damage is reduced in this process. STUDY DESIGN, SIZE, DURATION: This is a blinded, controlled laboratory study of differences in standard semen analysis parameters and the DNA fragmentation index (DFI) in split samples from infertile men (n = 70) that were discarded after routine semen analysis at an academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm concentration, progressive motility and forward progression were assessed by microscopic examination. For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation with swim-up or sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by sperm chromatin dispersion assay. The DFI was calculated, from up to 300 cells per slide, as the number of cells with fragmented DNA divided by the number of cells counted per slide. MAIN RESULTS AND THE ROLE OF CHANCE: The median DFI in unprocessed samples was 21% (interquartile range (IQR): 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation (P = 0.0029) and unprocessed samples (P < 0.0001). The median DFI for chip specimens was 0% (IQR: 0-2.4) while those processed by Density-Gradient Centrifugation had a median DFI of 6% (IQR: 2-11). Unprocessed samples in the highest DFI quartile (DFI range: 31-40%) had a median DFI of 15% (IQR: 11-19%) after Density-Gradient Centrifugation and DFI of 0% (IQR: 0-1.9%) after processing with the microfluidic chip (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: While a high DFI has been associated with poor outcomes with IVF/ICSI, there are limited data illustrating improvements in clinical outcomes with a reduction in DFI. As this study utilized discarded, non-clinical samples, clinical outcomes data are not available. WIDER IMPLICATIONS OF THE FINDINGS: While microfluidic sorting of unprocessed semen allowed for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation, standard processing by Density-Gradient Centrifugation with swim-up did not increase DNA fragmentation in an infertile population. The proposed microfluidic technology offers a flow-free approach to sort sperm, requiring no peripheral equipment or filtration step, while minimizing hands-on time. STUDY FUNDING/COMPETING INTEREST(S): No external funding to declare. Utkan Demirci, PhD is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc. and Koek Biotech. Mitchell Rosen, MD is a member of the Clinical Advisory Board for DxNow Inc.

Molly M Quinn - One of the best experts on this subject based on the ideXlab platform.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation in split semen samples
    Reproductive Biomedicine Online, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    Capsule Microfluidic sorting of unprocessed semen allows for the selection of clinically usable sperm with lower DNA fragmentation than standard processing. Objective To determine if microfluidic sorting improves the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation. Design Blinded, controlled laboratory study. Setting Academic medical center. Specimens Consecutively collected routine semen analysis samples (n=70). Intervention(s) For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation and sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by Sperm Chromatin Dispersion (SCD) test. Outcome Measure DNA Fragmentation Index (DFI) was calculated as number of cells with fragmented DNA divided by the number of cells counted per slide. Results The median DFI in unprocessed samples was 21% (IQR 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation and unprocessed samples. The median DFI for chip specimens was 0% (IQR 0–2.4) while those processed by Density Gradient Centrifugation had a median DFI of 6% (IQR 2-11). Unprocessed samples in the highest DFI quartile (DFI range 31–40%) had median DFI of 15% (IQR 11–19%) after Density-Gradient Centrifugation and DFI 0% (IQR 0–1.9%) after processing with the microfluidic chip (p = 0.02). Conclusion Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. Future studies will be expending the sample size, and validate if the use of chip can be translated into difference in pregnancy rates. Conflict of Interest Disclosures Utkan Demirci, Ph.D. is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc., and Koek Biotech. Mitchell Rosen, M.D. is a member of the Clinical Advisory Board for DxNow Inc. Funding None.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation with swim up in split semen samples
    Human Reproduction, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    STUDY QUESTION: Does microfluidic sorting improve the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation? SUMMARY ANSWER: Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. WHAT IS KNOWN ALREADY: Microfluidic devices have been explored to sort motile and morphologically normal sperm from a raw sample without Centrifugation; however, it is uncertain whether DNA damage is reduced in this process. STUDY DESIGN, SIZE, DURATION: This is a blinded, controlled laboratory study of differences in standard semen analysis parameters and the DNA fragmentation index (DFI) in split samples from infertile men (n = 70) that were discarded after routine semen analysis at an academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm concentration, progressive motility and forward progression were assessed by microscopic examination. For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation with swim-up or sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by sperm chromatin dispersion assay. The DFI was calculated, from up to 300 cells per slide, as the number of cells with fragmented DNA divided by the number of cells counted per slide. MAIN RESULTS AND THE ROLE OF CHANCE: The median DFI in unprocessed samples was 21% (interquartile range (IQR): 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation (P = 0.0029) and unprocessed samples (P < 0.0001). The median DFI for chip specimens was 0% (IQR: 0-2.4) while those processed by Density-Gradient Centrifugation had a median DFI of 6% (IQR: 2-11). Unprocessed samples in the highest DFI quartile (DFI range: 31-40%) had a median DFI of 15% (IQR: 11-19%) after Density-Gradient Centrifugation and DFI of 0% (IQR: 0-1.9%) after processing with the microfluidic chip (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: While a high DFI has been associated with poor outcomes with IVF/ICSI, there are limited data illustrating improvements in clinical outcomes with a reduction in DFI. As this study utilized discarded, non-clinical samples, clinical outcomes data are not available. WIDER IMPLICATIONS OF THE FINDINGS: While microfluidic sorting of unprocessed semen allowed for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation, standard processing by Density-Gradient Centrifugation with swim-up did not increase DNA fragmentation in an infertile population. The proposed microfluidic technology offers a flow-free approach to sort sperm, requiring no peripheral equipment or filtration step, while minimizing hands-on time. STUDY FUNDING/COMPETING INTEREST(S): No external funding to declare. Utkan Demirci, PhD is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc. and Koek Biotech. Mitchell Rosen, MD is a member of the Clinical Advisory Board for DxNow Inc.

Nathan E Wolins - One of the best experts on this subject based on the ideXlab platform.

  • Current Protocols in Cell Biology - Isolation of Lipid Droplets from Cells by Density Gradient Centrifugation.
    Current protocols in pharmacology, 2016
    Co-Authors: Dawn L Brasaemle, Nathan E Wolins
    Abstract:

    Abstract Lipid droplets are organelles found in most mammalian cells, as well as various plant tissues and yeast. They are composed of a core of neutral lipids surrounded by a membrane monolayer of phospholipids and cholesterol into which specific proteins are embedded. This unit provides protocols for isolating lipid droplets from mammalian cells by discontinuous Density Gradient Centrifugation.

  • unit 3 15 isolation of lipid droplets from cells by Density Gradient Centrifugation
    Current protocols in pharmacology, 2006
    Co-Authors: Dawn L Brasaemle, Nathan E Wolins
    Abstract:

    Lipid droplets are organelles found in most mammalian cells, as well as in various plant tissues and yeast. They are composed of a core of neutral lipids surrounded by a membrane monolayer of phospholipids and cholesterol in which specific proteins are embedded. This unit provides protocols for isolating lipid droplets from mammalian cells by discontinuous Density Gradient Centrifugation. © 2016 by John Wiley & Sons, Inc. Keywords: cell cultures; mammalian; preparation of lipid droplets by Centrifugation; Density-Gradient Centrifugation; isolation of lipid droplets

  • isolation of lipid droplets from cells by Density Gradient Centrifugation
    Current protocols in pharmacology, 2005
    Co-Authors: Dawn L Brasaemle, Nathan E Wolins
    Abstract:

    : Lipid droplets are organelles found in most mammalian cells, as well as in various plant tissues and yeast. They are composed of a core of neutral lipids surrounded by a membrane monolayer of phospholipids and cholesterol in which specific proteins are embedded. This unit provides protocols for isolating lipid droplets from mammalian cells by discontinuous Density Gradient Centrifugation. © 2016 by John Wiley & Sons, Inc.

L Jalalian - One of the best experts on this subject based on the ideXlab platform.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation in split semen samples
    Reproductive Biomedicine Online, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    Capsule Microfluidic sorting of unprocessed semen allows for the selection of clinically usable sperm with lower DNA fragmentation than standard processing. Objective To determine if microfluidic sorting improves the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation. Design Blinded, controlled laboratory study. Setting Academic medical center. Specimens Consecutively collected routine semen analysis samples (n=70). Intervention(s) For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation and sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by Sperm Chromatin Dispersion (SCD) test. Outcome Measure DNA Fragmentation Index (DFI) was calculated as number of cells with fragmented DNA divided by the number of cells counted per slide. Results The median DFI in unprocessed samples was 21% (IQR 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation and unprocessed samples. The median DFI for chip specimens was 0% (IQR 0–2.4) while those processed by Density Gradient Centrifugation had a median DFI of 6% (IQR 2-11). Unprocessed samples in the highest DFI quartile (DFI range 31–40%) had median DFI of 15% (IQR 11–19%) after Density-Gradient Centrifugation and DFI 0% (IQR 0–1.9%) after processing with the microfluidic chip (p = 0.02). Conclusion Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. Future studies will be expending the sample size, and validate if the use of chip can be translated into difference in pregnancy rates. Conflict of Interest Disclosures Utkan Demirci, Ph.D. is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc., and Koek Biotech. Mitchell Rosen, M.D. is a member of the Clinical Advisory Board for DxNow Inc. Funding None.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation with swim up in split semen samples
    Human Reproduction, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    STUDY QUESTION: Does microfluidic sorting improve the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation? SUMMARY ANSWER: Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. WHAT IS KNOWN ALREADY: Microfluidic devices have been explored to sort motile and morphologically normal sperm from a raw sample without Centrifugation; however, it is uncertain whether DNA damage is reduced in this process. STUDY DESIGN, SIZE, DURATION: This is a blinded, controlled laboratory study of differences in standard semen analysis parameters and the DNA fragmentation index (DFI) in split samples from infertile men (n = 70) that were discarded after routine semen analysis at an academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm concentration, progressive motility and forward progression were assessed by microscopic examination. For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation with swim-up or sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by sperm chromatin dispersion assay. The DFI was calculated, from up to 300 cells per slide, as the number of cells with fragmented DNA divided by the number of cells counted per slide. MAIN RESULTS AND THE ROLE OF CHANCE: The median DFI in unprocessed samples was 21% (interquartile range (IQR): 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation (P = 0.0029) and unprocessed samples (P < 0.0001). The median DFI for chip specimens was 0% (IQR: 0-2.4) while those processed by Density-Gradient Centrifugation had a median DFI of 6% (IQR: 2-11). Unprocessed samples in the highest DFI quartile (DFI range: 31-40%) had a median DFI of 15% (IQR: 11-19%) after Density-Gradient Centrifugation and DFI of 0% (IQR: 0-1.9%) after processing with the microfluidic chip (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: While a high DFI has been associated with poor outcomes with IVF/ICSI, there are limited data illustrating improvements in clinical outcomes with a reduction in DFI. As this study utilized discarded, non-clinical samples, clinical outcomes data are not available. WIDER IMPLICATIONS OF THE FINDINGS: While microfluidic sorting of unprocessed semen allowed for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation, standard processing by Density-Gradient Centrifugation with swim-up did not increase DNA fragmentation in an infertile population. The proposed microfluidic technology offers a flow-free approach to sort sperm, requiring no peripheral equipment or filtration step, while minimizing hands-on time. STUDY FUNDING/COMPETING INTEREST(S): No external funding to declare. Utkan Demirci, PhD is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc. and Koek Biotech. Mitchell Rosen, MD is a member of the Clinical Advisory Board for DxNow Inc.

Salustiano Ribeiro - One of the best experts on this subject based on the ideXlab platform.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation in split semen samples
    Reproductive Biomedicine Online, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    Capsule Microfluidic sorting of unprocessed semen allows for the selection of clinically usable sperm with lower DNA fragmentation than standard processing. Objective To determine if microfluidic sorting improves the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation. Design Blinded, controlled laboratory study. Setting Academic medical center. Specimens Consecutively collected routine semen analysis samples (n=70). Intervention(s) For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation and sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by Sperm Chromatin Dispersion (SCD) test. Outcome Measure DNA Fragmentation Index (DFI) was calculated as number of cells with fragmented DNA divided by the number of cells counted per slide. Results The median DFI in unprocessed samples was 21% (IQR 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation and unprocessed samples. The median DFI for chip specimens was 0% (IQR 0–2.4) while those processed by Density Gradient Centrifugation had a median DFI of 6% (IQR 2-11). Unprocessed samples in the highest DFI quartile (DFI range 31–40%) had median DFI of 15% (IQR 11–19%) after Density-Gradient Centrifugation and DFI 0% (IQR 0–1.9%) after processing with the microfluidic chip (p = 0.02). Conclusion Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. Future studies will be expending the sample size, and validate if the use of chip can be translated into difference in pregnancy rates. Conflict of Interest Disclosures Utkan Demirci, Ph.D. is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc., and Koek Biotech. Mitchell Rosen, M.D. is a member of the Clinical Advisory Board for DxNow Inc. Funding None.

  • microfluidic sorting selects sperm for clinical use with reduced dna damage compared to Density Gradient Centrifugation with swim up in split semen samples
    Human Reproduction, 2018
    Co-Authors: Molly M Quinn, L Jalalian, Salustiano Ribeiro, Utkan Demirci, Marcelle I Cedars, Mitchell P Rosen
    Abstract:

    STUDY QUESTION: Does microfluidic sorting improve the selection of sperm with lower DNA fragmentation over standard Density-Gradient Centrifugation? SUMMARY ANSWER: Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. WHAT IS KNOWN ALREADY: Microfluidic devices have been explored to sort motile and morphologically normal sperm from a raw sample without Centrifugation; however, it is uncertain whether DNA damage is reduced in this process. STUDY DESIGN, SIZE, DURATION: This is a blinded, controlled laboratory study of differences in standard semen analysis parameters and the DNA fragmentation index (DFI) in split samples from infertile men (n = 70) that were discarded after routine semen analysis at an academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm concentration, progressive motility and forward progression were assessed by microscopic examination. For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by Density-Gradient Centrifugation with swim-up or sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by sperm chromatin dispersion assay. The DFI was calculated, from up to 300 cells per slide, as the number of cells with fragmented DNA divided by the number of cells counted per slide. MAIN RESULTS AND THE ROLE OF CHANCE: The median DFI in unprocessed samples was 21% (interquartile range (IQR): 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by Density-Gradient Centrifugation (P = 0.0029) and unprocessed samples (P < 0.0001). The median DFI for chip specimens was 0% (IQR: 0-2.4) while those processed by Density-Gradient Centrifugation had a median DFI of 6% (IQR: 2-11). Unprocessed samples in the highest DFI quartile (DFI range: 31-40%) had a median DFI of 15% (IQR: 11-19%) after Density-Gradient Centrifugation and DFI of 0% (IQR: 0-1.9%) after processing with the microfluidic chip (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: While a high DFI has been associated with poor outcomes with IVF/ICSI, there are limited data illustrating improvements in clinical outcomes with a reduction in DFI. As this study utilized discarded, non-clinical samples, clinical outcomes data are not available. WIDER IMPLICATIONS OF THE FINDINGS: While microfluidic sorting of unprocessed semen allowed for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation, standard processing by Density-Gradient Centrifugation with swim-up did not increase DNA fragmentation in an infertile population. The proposed microfluidic technology offers a flow-free approach to sort sperm, requiring no peripheral equipment or filtration step, while minimizing hands-on time. STUDY FUNDING/COMPETING INTEREST(S): No external funding to declare. Utkan Demirci, PhD is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc. and Koek Biotech. Mitchell Rosen, MD is a member of the Clinical Advisory Board for DxNow Inc.